Corvidane is developing Corvida™ to treat TWO formidable diseases. Corvidane uses a novel approach to treat metabolic and inflammatory diseases. Corvida(TM) for Atherosclerosis - In development to be a Best-in-Class, orally administered adjunct to lipid regulating therapies (Statins/PCSK9) that targets atherosclerotic plaques, the major factor in Heart Attacks and Stroke. Corvida(TM) for NASH - In development to be a Best-in-Class, orally administered drug to treat NASH, which is the leading cause of liver transplants in the United States.